http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
EyePoint Pharmaceuticals Presents Positive YUTIQ™ 36-month Follow-up Phase 3 Data at the 2019 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
-
EyePoint Pharmaceuticals Announces First Quarter 2019 Financial Results Release Date and Conference Call Information
-
EyePoint Pharmaceuticals Reports Fiscal Period Ended December 31, 2018 Financial Results and Highlights Recent Clinical and Operational Developments
-
EyePoint Pharmaceuticals (EYPT) Launches DEXYCUTM 9% in U.S.
-
EyePoint Pharmaceuticals Announces U.S. Commercial Launch of DEXYCUTM (dexamethasone intraocular suspension) 9%
-
EyePoint Pharmaceuticals Announces Fiscal Period Ended December 31, 2018 Financial Results Release Date and Conference Call Information
-
EyePoint Pharmaceuticals Secures Up to $60 Million Debt Facility
-
EyePoint Pharmaceuticals (EYPT) Reports U.S. Commercial Launch of YUTIQ (fluocinolone acetonide intravitreal implant) 0.18 mg
-
EyePoint Pharmaceuticals Announces U.S. Commercial Launch of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg
-
EyePoint Pharmaceuticals (EYPT) Announces David Guyer MD to Board
-
EyePoint Pharmaceuticals Appoints David Guyer, M.D., to Board of Directors
-
EyePoint Pharmaceuticals Provides 2019 Commercial Update
-
EyePoint Pharmaceuticals Added to NASDAQ Biotechnology Index
-
EyePoint Pharmaceuticals Appoints Ron Honig, Esq., as SVP, General Counsel & Company Secretary
-
EyePoint Pharmaceuticals (EYPT) Reports Assignment of Permanent J-Code for DEXYCU from Center for Medicare and Medicaid Services
-
EyePoint Pharmaceuticals Announces Assignment of Permanent J-Code for DEXYCU™ by the Center for Medicare and Medicaid Services (CMS)
-
EyePoint Pharmaceuticals to Present at the Stifel 2018 Healthcare Conference
-
EyePoint Pharmaceuticals Reports Fiscal First Quarter 2019 Financial Results and Highlights Recent Clinical and Operational Developments
-
EyePoint Pharmaceuticals (EYPT), Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize Durasert
-
EyePoint Pharmaceuticals and Ocumension Therapeutics Sign Exclusive License Agreement to Develop and Commercialize Durasert™ Three-Year Treatment for Posterior Segment Uveitis in the Greater China R
-
EyePoint Pharmaceuticals Announces First Quarter Fiscal Year 2019 Financial Results Release Date and Conference Call Information
-
EyePoint Pharmaceuticals (EYPT) Announces John Landis, Ph.D., M.S., to Board
-
EyePoint Pharmaceuticals Appoints John Landis, Ph.D., M.S., to Board of Directors
-
EyePoint Pharmaceuticals (EYPT) Highlights Positive YUTIQ 24-Month Follow-Up Data at AAO 2018 Annual Meeting
-
EyePoint Pharmaceuticals Presents Positive YUTIQ™ 24-month Follow-up Data at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting
-
EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ™ to be Presented at the American Academy of Ophthalmology (AAO) 2018 Annual Meeting
-
EyePoint Pharmaceuticals (EYPT) Reports FDA Approval of YUTIQ (fluocinolone acetonide intravitreal implant)
-
EyePoint Pharmaceuticals Receives FDA Approval of YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg
-
EyePoint Pharmaceuticals Announces Proceeds of $28.9 Million from Exercised Warrants
-
EyePoint Pharmaceuticals Reports Fiscal 2018 Fourth Quarter & Full Year Financial Results and Highlights Recent Progress
-
EyePoint Pharmaceuticals (EYPT) Reports Election of Goran Ando M.D. as Next Board Chairman
-
EyePoint Pharmaceuticals Elects Göran Ando, M.D. as Next Chairman of Board of Directors
-
EyePoint Pharmaceuticals Secures Pass-through Payment Status and Assignment of C-Code for DEXYCU™
-
EyePoint Pharmaceuticals Announces Fiscal 2018 Fourth Quarter & Full Year Financial Results Release Date and Conference Call Information
-
EyePoint Pharmaceuticals to Present at Upcoming Investor Conferences
-
EyePoint Pharmaceuticals Appoints John Weet, Ph.D., as SVP, Regulatory Affairs & Quality
-
EyePoint Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
EyePoint Pharmaceuticals to Present at the 38th Annual Canaccord Genuity Growth Conference
-
EyePoint Pharmaceuticals (EYPT) Names David Price as CFO
-
EyePoint Pharmaceuticals Appoints David Price as Chief Financial Officer
-
EyePoint Pharmaceuticals Announces Presentation of Data Highlighting YUTIQ™ for Posterior Segment Uveitis at the 36th Annual Scientific Meeting of the American Society of Retina Specialists
-
EyePoint Pharmaceuticals (EYPT) Announces Data Highlighting YUTIQ for Posterior Segment Uveitis to be Presented at ASRS
-
EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ™ for Posterior Segment Uveitis to be Presented at the 36th Annual Scientific Meeting of the American Society of Retina Specialists
-
EyePoint Pharmaceuticals Appoints Göran Ando, M.D., to Board of Directors
-
EyePoint Pharmaceuticals Announces Stockholder Approval of Second Tranche of Capital Financing
-
EyePoint Pharmaceuticals Announces Appointment of Leonard Blum as Executive Vice President and General Manager, U.S.
-
EyePoint Pharmaceuticals Reports Fiscal Third Quarter 2018 Results
-
EyePoint Pharmaceuticals Announces Third Quarter Fiscal Year 2018 Financial Results Release Date and Conference Call Information
-
EyePoint Pharmaceuticals’ YUTIQ™ for Posterior Segment Uveitis to be Presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
-
EyePoint Pharma (EYPT) Strengthens Global IP with Notices of Allowance for Two U.S. Patents Related to DEXYCU
